<DOC>
	<DOCNO>NCT02016534</DOCNO>
	<brief_summary>This multi-centre Phase 2 study . The study evaluate activity safety AMG 337 patient MET amplify gastric , gastroesophageal junction esophageal adenocarcinoma MET amplify solid tumor . The study design estimate objective response rate AMG 337 tumor type .</brief_summary>
	<brief_title>Phase 2 Study AMG 337 MET Amplified Gastric/Esophageal Adenocarcinoma Other Solid Tumors</brief_title>
	<detailed_description>This phase 2 , multicenter , single arm , 2 cohort study ass safety , efficacy pharmacokinetics AMG 337 MET amplify Gastric/esophageal adenocarcinoma solid tumor . Approximately 140 subject enrol either Cohort 1 ( subject MET amplify G/E adenocarcinoma measurable tumor ) Cohort 2 ( subject MET amplify solid tumor measurable tumor/up 10 subject MET amplify G/E adenocarcinoma non-measurable tumor/up 10 subject receive prior MET antibody therapy ) . All subject self-administer AMG 337 300 mg daily disease progression protocol specify end treatment criterion meet . Tumor tissue , biomarkers , Pharmacokinetics Patient report Outcomes assess . Tumor assessment RECIST 1.1 follow study treatment .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Able daily selfadminister AMG 337 orally whole capsule Male female 18 year age . Pathologically confirm advanced G/GEJ/E adenocarcinoma ( Cohort 1 ) solid tumor ( Cohort 2 ) subject receive prior therapy advance disease , standard therapy exists , subject refuse standard therapy Tumor MET amplify protocolspecified centralized testing . Measurable disease per RECIST 1.1 guideline . Cohort 2 may include 10 subject advance MET amplify , G/GEJ/E adenocarcinoma nonmeasurable tumor per RECIST v1.1 ( ECOG ) Performance Status 0 , 1 2 Known central nervous system metastases Candidate curative surgery definitive chemoradiation Peripheral edema &gt; grade 1 Persistent gastric outlet obstruction , complete dysphagia dependent upon jejunostomy feeding . Significant gastrointestinal disorder ( ) opinion Investigator may influence drug absorption Acute Hepatitis B . Chronic Hepatitis B eligible condition stable , opinion investigator Amgen physician , consult , would pose risk subject safety Detectable Hepatitis C virus ( indicative active Hepatitis C ) Currently receive antitumor treatment , less 14 day prior enrollment since end antitumor treatment Prior treatment small molecule inhibitor MET pathway . Other protocol define inclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MET Amplified Gastric / Gastroesophageal Junction / Esophageal Adenocarcinoma , solid tumor .</keyword>
</DOC>